FUJIFILM Cellular Dynamics
March 2019
ApplicationsTrendingArticlesUpcoming Events
CDI
Welcome
Applications
Cellular Dynamics

See the Full Range of Cardiomyocyte Toxicity Applications from Molecular Devices

See how Molecular Devices has incorporated iCell Cardiomyocytes and Cardiomyocytes2 into high-throughput toxicity assays:

Phenotypic Characterization of Toxic Compound Effects on Cardiomyocytes Derived from Induced Pluripotent Stem Cells

High Throughput Cardiotoxicity Assays Using Stem Cell-Derived Cardiomyocytes

Cardiomyocyte Beating and Cytotoxicity Assays on the SpectraMax i3 Multi-Mode Microplate Platform with SpectraMax MiniMax Imaging Cytometer

Trending
Cellular Dynamics

FCDI iCell Cardiomyoctes in Recent Cardiotoxicity Presentations

See a collection of recent talks and poster presentations featuring iCell Cardiomyocytes:

hiPSC-CMs in Safety and Toxicity Testing - Diversity, Disease Modeling, and Resolving the Reversed Rate Effect of Calcium Channel Blockers
SOT 2019, Haoyu Zeng, Merck and T.K. Feaster, FCDI

The Utility of Electrical Field Stimulation for Functional Maturation of hiPSC-CM & Assessment of Inotropic Compounds
SOT 2019, Xiaoyu Zhang, ACEA and T.K. Feaster, FCDI

Prediction of Liabilities with Chronic Drug Treatment in iPSC Derived Cardiomyocytes using an MEA Platform
SOT 2019, Christopher Strock, Cyprotex

Predicting Tyrosine Kinase Inhibitor Cardiotoxicity with a Biomarker-Based Human iPSC-Derived Cardiomyocyte Assay
SOT 2019, Jessica Palmer, Stemina

Characterization of the Local Extracellular Action Potential (LEAP) Signal for Use in Cardiac Safety Evaluation
SPS 2018, Clements, M. Hayes, H.B. et al., Axion

Using Electrical Field Stimulation for Maturation of hiPSC Cardiomyocytes Assessment of Ionotropic Compounds and Cardiac Safety Assessment
FDA 2019, Yama Abassi, Axion


Articles
Cellular Dynamics

Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-derived Cardiomyocytes

An interesting comparison of the response of optically paced and unpaced iCell Cardiomyocytes2 to a panel of 28 blinded CiPA compounds with defined arrhythmogenicity.

Patel D., Stohlman J., Dang Q., Strauss D.G., and Blinova K. (2019) Toxicol. Sci.

SEE THE ARTICLE >>

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

See the comprehensive CiPA study on the performance of iCell Cardiomyocytes2 for the detection of drug-induced proarrhythmic effects

Ksenia Blinova, Qianyu Dang, Daniel Millard, et al. (2018) Cell Reports 24.

SEE THE ARTICLE >>

 
Upcoming Events
Cellular Dynamics

ISSCR 2019 Jun 26 - 29 | Los Angeles CA
Join FCDI at the important stem cell research meeting. More details on specific FCDI activities at ISSCR 2019 to come soon. Come visit us at
Booth # 412

MEETING DETAILS >>

Follow UsFCDI TwitterFCDI LinkedInFCDI FacebookFCDI Youtube